GELS vs IMRN
Gelteq Ltd. and Immuron Ltd., side by side — 2 fiscal years reported in AUD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | GELS | IMRN |
|---|---|---|
| Revenue | AUD 165,645 | AUD 7.3M |
| Net income | $-6.6M | AUD -5.2M |
| Gross margin | 30.3% | 65.4% |
| Net margin | −4011.9% | −71.6% |
| Return on equity | — | — |
| Diluted EPS | −AUD 0.72 | −AUD 2.26 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | AUD -5.5M | — |
| Equity | — | — |
| Net debt / equity | — | — |
| Current ratio | 0.27× | 5.09× |
| Revenue CAGR 5y | — | 23.7% |
| Profit CAGR 5y | — | — |
IMRN bills 44.0× the revenue of GELS, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
2 years side by side
| Fiscal year | GELS | IMRN |
|---|---|---|
| FY2024 | AUD 165,645 | AUD 7.3M |
| FY2022 | AUD 79,843 | AUD 1.8M |
Net income by year
Bottom line
| Fiscal year | GELS | IMRN |
|---|---|---|
| FY2024 | $-6.6M | AUD -5.2M |
| FY2022 | — | AUD -3.8M |